Results 101 to 110 of about 103,990 (261)

Low vision intervention in end-stage corneal disease. [PDF]

open access: yesIndian J Ophthalmol
Natarajan R   +3 more
europepmc   +1 more source

Japanese Clinical Practice Guidelines for Vascular Tumors, Vascular Malformations, Lymphatic Malformations, and Lymphangiomatosis 2022

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT The objective was to prepare guidelines to perform the current optimum treatment by organizing effective and efficient treatments of hemangiomas and vascular malformations, confirming the safety, and systematizing treatment, employing evidence‐based medicine techniques and aimed at improvement of the outcomes.
Yoshiaki Kinoshita   +116 more
wiley   +1 more source

Cover and Masthead

open access: yesVision Pan-America, 2014
Paulo E.C. Dantas
doaj   +3 more sources

Corneal biomechanical cues mediated by PAI-2: the origin of PM2.5-induced corneal disease. [PDF]

open access: yesEMBO Mol Med
Hao S   +20 more
europepmc   +1 more source

Real‐World Outcomes of Baricitinib and Ritlecitinib in Refractory Alopecia Areata: Response Predictors and Relapse After Discontinuation or Dose Reduction

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Baricitinib and ritlecitinib are newly approved systemic Janus kinase (JAK) inhibitors for severe, refractory alopecia areata (AA). Although clinical trials have demonstrated their efficacy, real‐world evidence remains limited, particularly regarding predictors of response and outcomes following treatment interruption or dose tapering.
Rina Hayashi   +2 more
wiley   +1 more source

Somos todos americanos!

open access: yesVision Pan-America, 2015
Paulo E.C. Dantas
doaj   +1 more source

Capabilities of Gabor-domain optical coherence microscopy for the assessment of corneal disease. [PDF]

open access: yesJ Biomed Opt, 2019
Tankam P   +8 more
europepmc   +1 more source

Mapping the lineage of prostate tissue ablation medical device predicates for focal therapy of prostate cancer approved via the FDA 510(k) clearance pathway

open access: yesSurgical Practice, EarlyView.
Abstract Objective Medical devices are reviewed by the US Food and Drug Administration (FDA) for safety and effectiveness. Class II devices can receive 510(k) clearance if they are “substantially equivalent” to an existing predicate device. This process can be repeated iteratively, leading to a lineage of predicates for newly cleared devices.
Yiting Lin   +3 more
wiley   +1 more source

Editorial: DMEK Revolution

open access: yesVision Pan-America, 2015
Paulo E.C. Dantas
doaj   +1 more source

Home - About - Disclaimer - Privacy